scb01a
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2011 (NCT01159522)
Timeline
Indications
Mechanism of action
- TubulinINHIBITOR
Tubulin inhibitor
- Tubulin beta-4B chain (TUBB4B) ↗
- Tubulin beta-1 chain (TUBB1) ↗
- Tubulin alpha-3C chain (TUBA3C) ↗
- Tubulin alpha-4A chain (TUBA4A) ↗
- Tubulin beta-3 chain (TUBB3) ↗
- Tubulin alpha-1A chain (TUBA1A) ↗
- Tubulin beta-4A chain (TUBB4A) ↗
- Tubulin beta-8 chain (TUBB8) ↗
- Tubulin beta chain (TUBB) ↗
- Tubulin alpha-1B chain (TUBA1B) ↗
- Tubulin alpha-1C chain (TUBA1C) ↗
- Tubulin alpha-3E chain (TUBA3E) ↗
- Tubulin beta-2A chain (TUBB2A) ↗
- Tubulin beta-2B chain (TUBB2B) ↗
- Tubulin beta-6 chain (TUBB6) ↗
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- scb01a
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03020823 | Phase 2 | Apr 30, 2017 | SynCore Biotechnology, Taipei Medical University |
| NCT02488629 | Phase 2 | Sep 1, 2015 | SynCore Biotechnology |
| NCT01151930 | N/A | Sep 1, 2011 | SynCore Biotechnology |
| NCT01159522 | Phase 1 | Apr 1, 2011 | SynCore Biotechnology |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| SynCore Biotechnology | For profit | 4 | 4 | 3 | 2011 |
| Taipei Medical University | Academic/Hospital | 1 | 0 | 1 | 2017 |
2 organizations
Page 1 / 1